Sputnik V, AstraZeneca booster dose trial result expected this week: Report

The Russian Direct Investment Fund (RDIF) has recently issued a statement regarding the trials conducted about the booster dose of Sputnik V and Astrazeneca trials which has not shown any adverse effects. According to news agency ANI more trials are still underway and it is expected to announce more results this week.

The government has also given its view on mixing of two vaccines for Covid-19. Minister of state for health Bharati Pravin Pawar in a written reply in the Rajya Sabha said,”Covid-19 vaccines have been developed recently. Therefore, scientific evidence about mix and match studies of different vaccines is still evolving.”

Meanwhile, Dr Reddy’s Laboratories issued a statement on 2 August regarding the availability of ‘Made in India’ Sputnik V COVID-19 doses from September /October, the Sputnik V team confirmed it was scaling up its vaccine production capacity.

Sputnik V team said in a statement,”Sputnik V team confirms that owing to a major scale-up in vaccine production capacity temporary second component delivery delays that occurred due to this production scale-up will be fully resolved in August.”

“Sputnik V has built production partnership with producers in 14 countries and will additionally double its capacity in September thanks to our partnership with top producers including Serum Institute of India, the world’s largest vaccine producer,” reads the statement.

“Sputnik V will also continue to play a leading role in vaccine combinations (mix and match approach). Sputnik V, which pioneered the heterogeneous boosting (vaccine cocktail) approach by using two different adenoviral vectors (Ad5 and Ad26) for two different shots, was first to offer a joint mix and match trial to another producer when it made an offer to AstraZeneca on November 23, 2020. Joint Sputnik V and AstraZeneca trials have been ongoing in the United Arab Emirates, Azerbaijan, and Argentina since February 2021. The early positive results were announced on July 30. More positive results on immunogenicity are expected this week,” it added.